共 188 条
[1]
Blanke CD(2008)Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 626-632
[2]
Rankin C(2013)Imatinib failture-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial J Clin Oncol 31 632s-1570
[3]
Demetri GD(2014)Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial J Clin Oncol 32 1563-1104
[4]
Ryan CW(2009)Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 1097-480
[5]
von Mehren M(2002)Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472-S41
[6]
Benjamin RS(2010)NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors J Natl Compr Canc Netw 8 S1-475
[7]
Raymond AK(2004)Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy Ann Surg Oncol 11 465-580
[8]
Bramwell VH(1998)Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577-1419
[9]
Baker LH(2008)Risk stratification of patients diagnosed with gastrointestinal stromal tumor Hum Pathol 39 1411-51
[10]
Maki RG(2013)Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation Cancer Chemother Pharmacol 71 43-949